Toggle navigation
Home
Search
Services
Blog
Contact
About
Antibody-Drug Conjugate Therapy for Cancer Treatment
Chari, Ravi V.
Immunogen, Inc., Cambridge, MA, United States
Search 16 grants from Ravi Chari
Search grants from Immunogen, Inc.
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Publications
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Mapping Elastic Properties and Composition of Cartilage Tissue
NH Childhood Lead Poisoning Prevention Program
Transient Gene Expression Leading to Lymphomagenesis
Regulation of Cranial Suture Morphogenesis
Maine Mhsip Project Stage II Continuation
Recently added grants:
Post-lysosomal cholesterol trafficking networks
Role of KCNQ2 channels in control of breathing
Mechanisms Controlling Expansion and Lineage Specification of Airway Progenitors in Development and Disease
Molecular regulation of Rho and Ras family GTPase activity controls vascular lumen formation.
New Signaling Networks in Vascular Smooth Muscle
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44CA056209-02A3
Application #
2008020
Study Section
Special Emphasis Panel (ZRG2-SSS-4 (02))
Project Start
1992-07-01
Project End
1999-03-31
Budget Start
1997-07-11
Budget End
1998-03-31
Support Year
2
Fiscal Year
1997
Total Cost
Indirect Cost
Institution
Name
Immunogen, Inc.
Department
Type
DUNS #
City
Cambridge
State
MA
Country
United States
Zip Code
02139
Related projects
NIH 1998
R44 CA
Antibody-Drug Conjugate Therapy for Cancer Treatment
Chari, Ravi V. / Immunogen, Inc.
NIH 1997
R44 CA
Antibody-Drug Conjugate Therapy for Cancer Treatment
Chari, Ravi V. / Immunogen, Inc.
Publications
Xie, Hongsheng; Audette, Charlene; Hoffee, Mary et al.
(2004)
Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice.
J Pharmacol Exp Ther 308:1073-82
Comments
Be the first to comment on this grant